Prevalence of MDR and ESBL producing Gram-negative isolates from various clinical samples from patients visiting a tertiary care hospital in Kathmandu, Nepal

Aryatara Shilpakar¹, Mehraj Ansari¹, Kulraj Rai², Ganesh Rai¹, and Shiba Kumar Rai¹,³

• ¹Shi-Gan International College of Science and Technology (SICOST), Tribhuvan University, Kathmandu, Nepal,
• ²Institute of Microbiology, University of Chinese Academy of Sciences, China,
• ³Nepal Medical College, Kathmandu, Nepal

Corresponding author: mrseeyon@gmail.com (Mehraj Ansari)

ABSTRACT

Background

The existence of multi-drug resistance organisms, including extended-spectrum beta-lactamases (ESBLs), is on the rise and is becoming a severe problem. Knowledge of the prevalence and antibiogram profile of such isolates is essential to develop an appropriate treatment methodology. This study aimed to study the prevalence of Gram-negative isolates exhibiting ESBL at a tertiary care hospital and study their antibiogram profile.

Methods

A cross-sectional study was conducted at Shahid Gangalal National Heart Centre, Kathmandu, Nepal, from June 2018 to November 2018. A total of 770 clinical samples were collected and identified by using the conventional biochemical tests following the Clinical and Laboratory Standard Institute (CLSI) guidelines. Antimicrobial susceptibility testing (AST) was performed using the Kirby Bauer disc diffusion method. The screening test for
ESBL producers was performed as recommended by the CLSI and the confirmatory test was performed phenotypically using the E-test.

Results

Out of 92 isolates, 84 (91.3%) isolates were multidrug resistant, and 47 (51.1%) isolates were found to be potential ESBL producers. Of these, 16 isolates were confirmed ESBL producers by the E-test. *Escherichia coli* and *Klebsiella pneumoniae* were the predominant isolates and were also the major ESBL producers. Besides polymyxin B (100% sensitive), meropenem and imipenem showed high efficacy against the ESBL producers.

Conclusion

Multidrug resistance was very high, however, ESBL production was low. Polymyxin B and carbapenems are the choice of drugs against ESBL producers but should be used only as the last line drugs.

Keywords: MDR, ESBL, Gram-negative isolates, carbapenems, polymyxin B, Nepal

BACKGROUND

Although advancements in medical technology continue to grow, the combat against drug-resistant microbes has always turned out to be challenging [1]. Bacteria have been ever-evolving and conferring resistance to more advanced and powerful antibacterial drugs. For instance, ESBL producers are capable of conferring resistance to beta-lactam antibiotics such as penicillins, cephalosporins, aztreonam, and so forth [2]. Moreover, ESBL producers often carry genes responsible for resistance to antimicrobial other than beta-lactamases, too [3]. Therefore, ESBLs producers exhibit broad antibiotic resistance, which makes them problematic for clinical therapeutics [3,4,5] and is responsible for increased morbidity and mortality due to unsuitable or
delayed antibiotic treatment, further increasing treatment costs [6]. The occurrence of ESBLs is becoming more common in Gram-negative isolates [7,8] and the number of ESBL producers is growing exponentially [9]. Many new classes of β-lactam antibiotics have been developed over the years, but the overuse of such antibiotics has resulted in the emergence of new variants of β-lactamases [10]. Hence, ESBL producers have become a major multidrug-resistant pathogen in the last two decades [11]. The problem is most noticeable in developing countries [1,11] and is due primarily to the haphazard use of antibiotics. And as expected, in Nepal, the prevalence is high as have been reported during the recent past [12,13,14,15]. The last decade has witnessed several significant changes in the ESBL producing isolates [11]. Hence, regular surveillance of ESBL production is needed to guide appropriate antimicrobial therapy [16] and minimize the risk of developing resistance with certain drugs soon [17]. Thus, we conducted a study to find out the prevalence and antimicrobial susceptibility pattern of ESBL producing Gram-negative bacteria isolated from different clinical samples at tertiary care hospitals.

METHODS

Study design

A hospital-based cross-sectional study was conducted for six months (June to November 2018) at Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Different clinical samples taken from patients admitted in the hospital and also from visiting outpatient departments of the hospital were included. In the case of urine and sputum, proper information about sample collection was given. Improperly collected samples or those lacking proper labeling were excluded from the study.

Isolation and identification of the isolates

A total of 770 samples (urine: 250, sputum: 185, pus: 115, blood: 166, wound swab: 49, and tissue: 5) were processed (cultured) following the CLSI guidelines. The specimens were cultured
on nutrient agar, brain heart infusion (BHI) broth (only for blood samples), MacConkey agar, and blood agar. The isolates were identified based on colony morphology, Gram's stain result, and conventional biochemical methods [18].

**Antimicrobial susceptibility testing**

Antimicrobial susceptibility testing (AST) was done by the Kirby-Bauer disk diffusion technique using Muller Hinton agar (MHA) [19]. The antibiotics used were amikacin (30µg), amoxyclav (30 µg), amoxicillin (10 µg), gentamicin (10 µg), ceftriaxone (30 µg), norfloxacin (10 µg), cotrimoxazole (25 µg), ciprofloxacin (5 µg), cefixime (30 µg), gentamicin (10 µg), nitrofurantoin (30 µg), nalidixic acid (30 µg), ofloxacin (5 µg), meropenem (10 µg), piperacillin/tazobactam (100/10), polymyxin B (100 IU), imipenem (10 µg), cefepime (30 µg). The bacterial isolates showing resistance towards three or more different antibiotics classes were considered multidrug-resistant (MDR) bacteria.

**Screening and confirmation of ESBL producers**

Ceftazidime, cefpodoxime, ceftriaxone, and cefotaxime were included in the primary panel for screening potential ESBL producers. Isolates showing resistance to any of these antibiotics were suspected as potential ESBL producers and were confirmed by E-test (Ezy MIC™). For this, a lawn culture of the test organism was done on MHA which the Ezy MIC™ strip was applied using the applicator, and reading was taken after incubation. Minimum inhibitory concentration (MIC) value (where the edge of the inhibition ellipse intersects the side of the strip) was noted. ESBL production was confirmed as positive when the ratio of the MIC value obtained for ceftazidime or ceftriaxone in combination with the clavulanic acid (CAZ+ or CTR+) was more than 8 or when no zone obtained for CTR or CAZ and zone obtained in CTR+ or CAZ+.

**Quality control**

All batches of the culture media and chemical reagents were processed with aseptic techniques following CLSI guidelines applying a standard aseptic procedure. In AST, quality control was maintained by using the control strains of *E. coli* ATCC 25922. Quality control of Ezy MIC™
strip was carried out by testing the strips with standard ATCC strains (*E. coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603).

**Data analysis**

SPSS v16.0 was used for statistical analysis. Chi-square test was applied at 95% CI among demographic variables.

**RESULTS**

A total of 92 Gram-negative bacteria were isolated from various clinical specimens. *K. pneumoniae* (n=35) and *E. coli* (n=29) were the predominant isolates. Highest number of the organism was isolated from urine (n=52) followed by sputum (n=18) (Table 1). A total of 39 and 50 organisms were isolated from the inpatient department and outpatient department, respectively. The highest number of organisms were isolated from the age-group above 60 and the least from the age-group 11-20 (Table 3). There was no significant difference in growth positivity between males and females (p=0.134); however, growth positivity in urine was significantly higher in females (77.3%) than in males (37.5%) (p=0.012).

**Table 1: Sample-wise distribution of isolates**

| Microorganisms       | Specimens |       |       |       |       |       | Total |
|----------------------|-----------|-------|-------|-------|-------|-------|-------|
|                      | Urine     | Sputum| Pus   | Blood | Wound | Tissue|       |
| *E. coli*            | 28        | 0     | 0     | 1     | 0     | 0     | 29    |
| *K. pneumoniae*      | 15        | 11    | 3     | 2     | 2     | 2     | 35    |
| *P. aeruginosa*      | 1         | 3     | 0     | 2     | 0     | 0     | 6     |
| Acinetobacter spp.   | 5         | 4     | 1     | 3     | 1     | 0     | 14    |
| Enterobacter spp.    | 1         | 0     | 0     | 0     | 1     | 0     | 2     |
| *P. mirabilis*       | 2         | 0     | 0     | 0     | 0     | 0     | 2     |
| *S. marcescens*      | 0         | 0     | 2     | 0     | 1     | 1     | 4     |
| **Total**            | **52**    | **18**| **6** | **8** | **5** | **2** | **92**|

**Antibiotic susceptibility pattern of Gram-negative isolates**

Of the 20 different antibiotics used, polymyxin B was the most effective drug (100% sensitivity), whereas amoxicillin (3.3% sensitivity) was the least effective (Table 2). In AST, 47 (51.1%) isolates showed resistance to one or more cephalosporin used and were suspected to be ESBL producers.
Antibiotic susceptibility pattern of ESBL producers

Of the 20 different antibiotics used against Gram-negative bacteria, polymyxin B showed 100% effectiveness to ESBL producers. Meropenem and imipenem were sensitive to around 75% of the four of the ESBL producers. Amoxycillin and Gentamicin were also effective against more than three-fifths of the ESBL producers. All other antibiotics used showed reduced sensitivity to the

Table 2: Organism-wise antibiotic resistance pattern

| Antibiotics      | $E. coli$ (n=29) | $K. pneumonia$ (n=35) | $P. aeruginosa$ (n=6) | $Acinetobacter$ (n=14) | $Enterobacter$ (n=2) | $P. mirabilis$ (n=2) | $S. marcescens$ (n=4) |
|------------------|------------------|-----------------------|-----------------------|-------------------------|----------------------|----------------------|------------------------|
| Amoxycillin      | 100.0%           | 94.3%                 | 100.0%                | 100.0%                  | 100.0%               | 100.0%               | 75.0%                  |
| Amikacin         | 34.5%            | 77.1%                 | 50.0%                 | 78.6%                   | 100.0%               | 0.0%                 | 50.0%                  |
| Ciprofloxacin    | 96.6%            | 88.6%                 | 66.7%                 | 100.0%                  | 0.0%                 | 100.0%               | 50.0%                  |
| Cotrimoxazole    | 65.5%            | 60.0%                 | 100.0%                | 100.0%                  | 100.0%               | 50.0%                | 50.0%                  |
| Gentamicin       | 27.6%            | 80.0%                 | 83.3%                 | 78.6%                   | 0.0%                 | 50.0%                | 0.0%                   |
| Nalidixic Acid   | 100.0%           | 97.1%                 | 100.0%                | 92.9%                   | 100.0%               | 100.0%               | 25.0%                  |
| Polymyxin B      | 0.0%             | 0.0%                  | 0.0%                  | 0.0%                    | 0.0%                 | 0.0%                 | 0.0%                   |
| Ofloxacin        | 96.6%            | 88.6%                 | 66.7%                 | 100.0%                  | 0.0%                 | 100.0%               | 50.0%                  |
| Amoxycyclav      | 79.3%            | 85.7%                 | 100.0%                | 92.9%                   | 100.0%               | 100.0%               | 0.0%                   |
| Ceftriaxone      | 86.2%            | 91.4%                 | 83.3%                 | 92.9%                   | 0.0%                 | 0.0%                 | 50.0%                  |
| Cefixime         | 100.0%           | 91.4%                 | 100.0%                | 100.0%                  | 0.0%                 | 0.0%                 | 25.0%                  |
| Ceftazidime      | 89.7%            | 91.4%                 | 83.3%                 | 100.0%                  | 100.0%               | 0.0%                 | 50.0%                  |
| Piperacillin tazobactam | 20.7% | 77.1% | 50.0% | 78.6% | 0.0% | 50.0% | 0.0% |
| Tobramycin       | 44.4%            | 80.0%                 | 40.0%                 | 78.6%                   | -                    | -                    | -                      |
| Cefepime         | 93.1%            | 91.4%                 | 50.0%                 | 85.7%                   | 100.0%               | 50.0%                | 25.0%                  |
| Meropenem        | 24.1%            | 60.0%                 | 50.0%                 | 64.3%                   | 0.0%                 | 0.0%                 | 0.0%                   |
| Imipenem         | 20.7%            | 57.1%                 | 50.0%                 | 78.6%                   | 0.0%                 | 0.0%                 | 25.0%                  |
| Nitrofurantoin   | 24.1%            | 74.3%                 | -                     | 85.7%                   | 100.0%               | 100.0%               | 50.0%                  |
| Norfloxacin      | 96.6%            | 88.6%                 | 66.7%                 | 100.0%                  | 0.0%                 | 100.0%               | 50.0%                  |
| Cepodoxime       | 93.1%            | 100.0%                | 83.3%                 | 78.6%                   | 100.0%               | 100.0%               | 50.0%                  |

Fig 1: Antibiotic resistance pattern of the ESBL and non-ESBL producers
ESBL producers as compared to the non-ESBL producing isolates (Fig 1).

**Distribution of ESBL producers in Gram-negative isolates**

Among the 47 suspected isolates, 16 (34.0%) were found to be ESBL producers. ESBL production was the highest in *E. coli* (39.3%), followed by *Acinetobacter* and *K. pneumoniae*. Other Gram-negative isolates, such as *Pseudomonas aeruginosa*, *Enterobacter* spp., *Proteus mirabilis*, and *Serratia marcescens*, did not show any ESBL activity (Fig 2).

![Distribution of MDR isolates and ESBL producers among total isolates](image)

Fig 2: Distribution of MDR isolates and ESBL producers among total isolates.

**Demographic distribution of MDR isolates and ESBL producers**

The prevalence of MDR was higher in males, whereas ESBL production was dominant in females. MDR prevalence was very high in all age groups. ESBL production was higher in the age-groups 31-40 years and 41-50 years. The percentage of MDR isolates was higher in outpatient compared to the inpatient, whereas ESBL production was higher in isolates from inpatient than the outpatient. Among the samples, MDR was seen very high, i.e., 80% or above, in isolates from all the samples except pus. ESBL producers were dominant in urine and absent in pus, wound, and tissue samples (Table 3).

**DISCUSSION**

In this study, 11.9% of the samples showed growth positivity. However, higher rates of growth positivity have been reported in similar studies in Nepal [20,21,22,23]. In this study, the highest number of growth was observed in the urine sample which was in agreement with that reported by
GC et al. [21] and Gurung et al. [24]. *K. pneumoniae* was the dominant isolate, followed by *E. coli* and *Acinetobacter* spp. GC et al. [21], Aryal et al. [22], and Guragain et al. [25] reported a higher prevalence of *E. coli* followed by *K. pneumoniae*. Karn et al. [20] reported a lower prevalence of *K. pneumoniae* and *P. aeruginosa* than ours. Similar culture positivity was seen in both sexes; however, culture positivity was higher for females than males in the urine sample, and a higher prevalence of *E. coli* and *K. pneumoniae* was observed. Similar outcomes were drawn by Saderi et al. [26] and Yadav and Prakash [27]. Another study by Shrestha et al. [28] also unveiled *E. coli* as the most common organism.

Table 3: Demographic distribution of MDR isolates and ESBL producers

| Characters  | Growth positive N (%) | MDR N (%) | p-value | ESBL producers N (%) | p-value |
|------------|-----------------------|-----------|---------|----------------------|---------|
| Sex        |                       |           |         |                      |         |
| Male (n=424) |                       |           |         |                      |         |
|           | 48 (11.3%)            | 46 (95.8%)| 0.146   | 7 (14.6%)            | 0.436   |
| Female (n=346) |                       |           |         |                      |         |
|           | 44 (12.7%)            | 38 (86.4%)|         | 9 (20.5%)            |         |
| Age-group  |                       |           |         |                      |         |
| <10 (n=123) |                       |           |         |                      |         |
|           | 12 (9.8%)             | 12 (100%) |         | 2 (16.7%)            |         |
| 11-20 (n=90) |                       |           |         |                      |         |
|           | 4 (4.4%)              | 3 (75%)   |         | 0 (0.0%)             |         |
| 21-30 (n=84) |                       |           |         |                      |         |
|           | 9 (10.7%)             | 8 (88.9%) | 0.77    | 5 (23.8%)            | 0.596   |
| 31-40 (n=105) |                      |           |         |                      |         |
|           | 21 (20.0%)            | 20 (95.2%)|         | 1 (11.1%)            |         |
| 41-50 (n=71) |                      |           |         |                      |         |
|           | 8 (11.3%)             | 7 (87.5%) | 0.016   | 3 (37.5%)            |         |
| 51-60 (n=101) |                      |           |         |                      |         |
|           | 11 (10.9%)            | 10 (90.9%)|         | 2 (18.2%)            |         |
| >60 (n=196)  |                      |           |         |                      |         |
|           | 27 (13.8%)            | 24 (88.9%)|         | 3 (11.1%)            |         |
| Department |                       |           |         |                      |         |
| Inpatient (n=503) |                   |           |         |                      |         |
|           | 33 (6.6%)             | 27 (81.8%)| 0.016   | 7 (21.2%)            | 0.693   |
| Outpatient (n=197) |                   |           |         |                      |         |
|           | 59 (29.9%)            | 57 (96.6%)|         | 9 (15.3%)            |         |
| Sample    |                       |           |         |                      |         |
| Urine (n=250) |                       |           |         |                      |         |
|           | 52 (20.8%)            | 47 (90.4%)|         | 12 (23.1%)           |         |
| Sputum (n=185) |                      |           |         |                      |         |
|           | 18 (9.7%)             | 18 (100%) |         | 3 (16.7%)            |         |
| Pus (n=115)  |                      |           |         |                      |         |
|           | 6 (5.2%)              | 4 (66.6%) | 0.195   | 0 (0.0%)             | 0.714   |
| Blood (n=166) |                      |           |         |                      |         |
|           | 8 (4.8%)              | 8 (100%)  |         | 1 (12.5%)            |         |
| Wound (n=49)  |                      |           |         |                      |         |
|           | 5 (10.2%)             | 4 (80%)   |         | 0 (0.0%)             |         |
| Tissue (n=5)   |                      |           |         |                      |         |
|           | 3 (60.0%)             | 2 (66.7%) |         | 0 (0.0%)             |         |
| n=770 | n=92 (11.9%) | n=84 (91.3%) | n=16 (17.4%) | | |

More than 90% of the Gram-negative isolates showed multi-drug resistance in this study. MDR was high in all the demographic characters studied. Most of the studies reported a lower MDR
than this study [15,29]. Panta et al. [30] have shown MDR rate in 100% of *Klebsiella* spp., and 80% of *Acinetobacter* spp. A study by Ghimire et al. [14] and Yadav et al. [31] recorded 96.8% and 82.5% of the isolates as MDR, respectively. Guragain et al. [25], Chakravarti et al. [32] and, Sharma et al. [33], reported a lower MDR rate than ours in urinary *E. coli* and *K. pneumoniae* isolates. Surprisingly, in our study, the percentage of MDR was seen higher in outpatients than inpatients which is in contrast with that reported by Shrestha et al. [28]. The increasing rate of MDR in outpatients found in this study might be due to non-empirical use, taking incomplete doses of antibiotics, and the easy availability of antibiotics without prescription.

ESBL producing bacteria are gradually increasing in hospital sectors, mostly as nosocomial infections, worldwide, and the occurrence of ESBL producing strains is changing rapidly over time with great variation [34]. In this study, ESBL producing bacteria was 17.4% of the total isolates. Kayastha et al. [15] and Raut et al. [35] reported a slightly higher prevalence of ESBL producing organisms whereas Yadav and Prakash [27], Biswas et al. [36], and Afridi et al. [37] reported a much higher rate. In this study, a greater number of ESBL producers were encountered from inpatients (21.2%) than outpatients (15.3%). Similar findings have been reported by Mishra et al. [12], and Khanfar et al. [38]. In this study, the highest ESBL producer was found in urine (25.5%) followed by sputum (16.7%) and blood (12.5%). This was consistent with the reports reported by Luzzaro et al. [7], Parajuli et al. [13], and Khanfar et al. [38] where the major source of ESBL producers were urinary tract infections. Sharma et al. [33], however, reported a slightly lower and Guragain et al. [25] reported a slightly higher rate of ESBL producing bacteria among the urinary isolates. Over one-third of *E. coli* was found to be the major ESBL producing isolate in this study and this was similar to that reported by Parajuli et al. [13], Ghimire et al. [14]. Yadav et al. [31] and Khanfar et al. [38] have also highlighted *E. coli* as the major ESBL producing bacteria. Kazemian et al. [39] reported higher ESBL production rates in *E.coli*, and *K. pneumoniae* than ours, whereas Sharma et al. [33] reported lower ESBL production in both strains. A study from Europe showed considerable variation, ranging from 1.6% (Latvia) to 23.2%
In the prevalence of ESBL-producing E. coli isolates [40]. The change in ESBL production pattern in bacteria seemed common as ESBLs were most often encoded on plasmids, which could easily be transferred between isolates [41,42].

In this study, most of the first-line drugs were found to be ineffective. Antibiotics belonging to third and fourth-generation cephalosporins, fluoroquinolones, amoxicillin, and amoxyclovain were found to be ineffective to ESBL producers and MDR strains. Khanfar et al. [38] have reported high levels of resistance to gentamicin, amikacin, amoxicillin-clavulanic acid, and ciprofloxacin. However, our findings showed greater susceptibility to amikacin and gentamicin. This might be due to the minimal use of such drugs for treatment. On the contrary, the high degree of resistance to cephalosporins and fluoroquinolones in our study might be due to over-dependent on such antibiotics. Ogefera et al. [43] have also reported a high level of resistance against amoxicillin-clavulanate, ceftazidine, ceftriaxone, gentamicin, ciprofloxacin, and ofloxacin by ESBL producers. The overall antibiogram of Gram-negatives in this study showed a decreased susceptibility against most of the antibiotics, including carbapenems. This might be due to the haphazard use of the drug in hospital settings and unnecessary prescriptions by physicians before the arrival of actual culture and sensitivity reports. A higher sensitivity was seen for polymyxin B (100%) and carbapenems in ESBL producers in our study. Higher sensitivity to carbapenems was also reported by Luzzaro et al. [7], Mishra et al. [12], Ghimire et al. [14], Shrestha et al. [28], Biswas et al. [36] and, Khanfar et al. [38] making them an ideal choice of drugs so far, for treating bacteria producing ESBL. All isolates showed sensitivity to polymyxin B. However, K. pneumoniae, P. aeruginosa, and Acinetobacter spp. showed greater resistance against most of the drugs except polymyxin B. All E. coli were sensitive to polymyxin B followed by imipenem. Polymyxin B and carbapenems seem to be the choice of drugs against ESBL producers and Gram-negative bacteria. However, these drugs should be considered as alternatives until we have other effective drugs that could be administered safely. As the drug sensitivity pattern of different
common Gram-negative bacteria seemed to change over time, a recent antibiogram for different Gram-negative isolates might help physicians in treating bacterial infections [44].

CONCLUSIONS

The present study revealed a very high MDR prevalence (91.3%) though ESBL production (19.0%) was low. Therefore, regular surveillance of MDR and ESBL producers and implementation of hospital infection control policies to prevent the transmission of such isolates is much required. Polymyxin B and carbapenems seem to be the choice of drugs against ESBL producers and Gram-negatives but should be considered as alternatives until we have other sensitive drugs that could be administered safely.

Limitations

There were a few limitations to our study. Firstly, the sample size was around 770, which seemed to be significantly less than in other studies. The study was conducted within a short duration, i.e., six months. The data taken was purely obtained from only one hospital, which might not represent the whole population. Only a phenotypic study was performed. Studies on the molecular level would have strengthened the findings.

List of abbreviations

ESBL: Extended-spectrum beta-lactamase, CLSI: Clinical and Laboratory Standard Institute, MDR: Multidrug Resistant, BHI: Brain Heart Infusion, MHA: Muller Hinton Agar, ATCC: American Type Culture Collection, E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, CI: Confidence Interval

Declarations

Ethical approval and consent to participate

The ethical consideration was obtained from the Research Review Committee of the National Institute of Tropical Medicine and Public Health Research (NITMPHR) center, Research, and Ethical committee, Shi-Gan, and NITMPHR Health Foundation Maharajgunj, Kathmandu, Nepal (IRC Reference No: 04/2071/08/26). Written informed consent was obtained from all the
participants above age 16 and the parent of children under 16 years before sample collection. All methods were carried out under relevant guidelines and regulations.

Consent for publication
Not applicable

Availability of data and materials
The datasets generated and analyzed during the current study are available in the appropriate materials repository (tables and figures).

Competing interests
The authors declared no conflicts of interest to the research, authorship, and publication of this article.

Funding
The authors received no financial support for the study, authorship, and publication of this article.

Authors' Contribution
All authors made substantial contributions to conception and design, research work, data analysis; took part in drafting the article or revising it; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work.

Acknowledgments
We would like to acknowledge the laboratory staff and research participants of ANIAS for their help and support. We are equally grateful to all the colleagues to all the people who directly or indirectly helped in completing this work.

REFERENCES
1. Aslam B, Wang W, Arshad MI, Khurshid M, Muzamil S, Rasool MH et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Res 2018;11:1645-8.
2. Paterson DL and Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev. 2005; 18 Suppl 4:657-86.
3. Peterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL). Clin Microbiol Infect. 2000;6:460-3.

4. Mammeri H, Loo MV, Poirel L, Martinez L, and Nordmann P. Emergence of plasmid-mediated quinolone resistance in E. coli in Europe. Antimicrob Agents Chemother. 2005; 49 Suppl 1:71-6.

5. Wang M, Sahm DF, Jacoby GA, and Hooper AD. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in K. pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004;48 Suppl 4:1295–9.

6. Knudsen JD, and Andersen SE. A Multidisciplinary intervention to reduce infections of ESBL- and AmpC-producing Gram-negative bacteria at a University Hospital. PLOS ONE 2014;9(1):e86457. doi:10.1371/journal.pone.0086457.

7. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G et al. Trends in production of extended-spectrum β-lactamases among Enterobacteria of medical interest: Report of the Second Italian Nationwide Survey. J Clin Microbiol. 2004;44:1659-64.

8. Song W, Kim J, Bae IK, Jeong SH, Seo YH, Shin JH et al. Chromosome-encoded AmpC and CTX-M extended-spectrum β-lactamases in clinical isolates of P. mirabilis from Korea. Antimicrob Agents Chemother. 2011;55:1414-9.

9. Sid Ahmed MA, Bansal D, Acharya A, Elmi AA, Hamid JM, Sid Ahmed AM et al. Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae from intensive care units at Hamad Medical Corporation, Qatar. Antimicrob Resist Infect Control. 2016;5:4. doi:10.1186/s13756-016-0103-x.

10. Agrawal P, Ghosh AN, Kumar S, Basu B, and Kapila K. Prevalence of extended-spectrum B-lactamases among E. coli and K. pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol. 2008;51:139-42.

11. Doi Y, Lovleva A, and Bonomo RA. The ecology of extended-spectrum B-lactamases (ESBLs) in the developed world. J Travel Med. 2017;24 Suppl 1:44-51.

12. Mishra SK, Sapkota GP, Adhikari S, and Lakhey M. Beta-lactamases in a Nepalese hospital: wake up before the "biological quake" destroys you. Int J Infect Dis. 2016;45S:103.

13. Parajuli NP, Maharjan P, Joshi G, and Khanal PR. Emerging perils of extended spectrum β-lactamase producing Enterobacteriaceae clinical isolates in a Teaching Hospital of Nepal. BioMed Res Int. 2016;3:1-7.
14. Ghimire A, Acharya B, and Tuladhar R. Extended spectrum β-lactamase (ESBL) producing multidrug-resistant Gram-negative bacteria from various clinical specimens of patients visiting a tertiary care hospital. TU J Microbiol. 2018;4 Suppl 1:1-8.

15. Kayastha K, Dhungel B, Karki S, Adhikari B, Banjara MR, Rijal KR, et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in pediatric patients visiting International Friendship Children's Hospital, Kathmandu, Nepal. Infect Dis. 2020;13:1-7.

16. Gautam V, Thakur A, Sharma M, Singh A, Bansal S, Sharma A, et al. Molecular characterization of extended-spectrum B-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae: A multi-centric study from tertiary care hospitals in India. Indian J Med Res. 2019;149:208-15.

17. Li B, and Webster TJ. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J Orthop Res. 2018;36 Suppl 1:22-32.

18. Cheesbrough M: District laboratory practice in Tropical Countries. Part 2. Cambridge University Press. UK. 2000;62-70.

19. CLSI (Clinical and Laboratory Standards Institute). Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Document M100-S29. Wayne, PA. 2010.

20. Karn S, Pant ND, Neupane S, Khatriwa S, Basnyat S, and Shrestha B. Prevalence of carbapenem-resistant bacterial strains isolated from different clinical samples: a study from a tertiary care hospital in Kathmandu, Nepal. J Biomed Sci. 2016;3 Suppl 1:11-5.

21. GC B, Sapkota NR, Rayamajhee B, Lamichhane J, Poudel P, Lekhak S, et al. Detection of blaNDM-1 gene among the carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from a children's hospital in Nepal. J Novel Research Microbiol. 2018;2 Suppl 5:65-74.

22. Aryal SC, Upreti MK, Ansari M, Nepal K, Dhungel B, Adhikari N, et al. Plasmid-mediated AmpCβ-lactamase CITM and DHAM genes among Gram-negative clinical isolates. Infect Drug Resist. 2020;3:4249-61.

23. Pokhrel H, Thapa B, Kafle R, Shah PK, and Tribuddharat C. Co-existence of beta-lactamas in clinical isolates of Escherichia coli from Kathmandu, Nepal. BMC Res Notes. 2014;7:694.

24. Gurung S, Kafle S, Dhungel B, Adhikari N, Shrestha U, Adhikari B, et al. Detection of OXA-48 gene in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from urine samples. Infect Drug Resist. 2020;13:2311-21.
25. Guragain N, Pradhan A, Dhungel B, Banjara MR, Rijal KR, and Ghimie P. Extended-spectrum beta-lactamase-producing Gram-negative bacterial isolates from the urine of patients visiting Everest Hospital, Kathmandu, Nepal. TU J Microbiol 2019;6 Suppl 1:26-31.

26. Saderi H, Owlia P, Nadoushan MRJ, Zaeri F, and Zandieh E. A 3-year study of demographic characteristics of patients with urinary tract infection, microbial etiology, and susceptibility of isolated bacteria to antibiotics in Shaheed Mostafa Khomeini Hospital. Iran J Pathol. 2006;1 Suppl 3:99-104.

27. Yadav K and Prakash S. Screening of ESBL producing multidrug-resistant E. coli from urinary tract infection suspected cases in Southern Terai of Nepal. J Infect Dis Diag. 2017;2 Suppl 2:1-8.

28. Shrestha D, Sherchand SP, Gurung K, Manandhar S, Shrestha B, and Sherchan S. Prevalence of multidrug-resistant extended-spectrum β-lactamase-producing bacteria from different clinical specimens in Kathmandu Model Hospital, Kathmandu, Nepal. EC Microbiol. 2016;4 Suppl 2:676-98.

29. Nepal K, Pant ND, Neupane B, Belbase A, Baidhya R, Shrestha RK, et al. Extended-spectrum beta-lactamase and Metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal. Ann Clin Microbiol Antimicrob. 2017;16 Suppl 1:62.

30. Panta K, Ghimire P, Rai SK, Mukhiya RK, Singh R, and Rai G. Antibiogram typing of Gram-negative isolates in different clinical samples of a tertiary hospital. Asian J Pharm Clin Res. 2016;6 Suppl 1:1153-6.

31. Yadav KK, Adhikari N, Khadka R, Pant AD, and Shah B. Multidrug-resistant Enterobacteriaceae and extended-spectrum β-lactamase producing Escherichia coli: a cross-sectional study in National Kidney Center, Nepal. Antimicrobial Resist Infect Control 2015;4(2):1-7.

32. Chakrawarti A, Dongol P, Khanal H, Subba P, and Banerjee JJ. Extended-spectrum beta-lactamases detection and multiple antibiotic resistance indexing of Escherichia coli from urine samples of patients from a referral hospital of Eastern Nepal. Int J Appl Sci Biotechnol 2015;3 Suppl 3:423-6.

33. Sharma KR, Bhandari P, Adhikari N, Tripathi P, Khanal S, and Tiwari BR. Extended-spectrum β-lactamase (ESBL) producing multi-drug resistant (MDR) urinary pathogens in a children's hospital from Nepal. Kathmandu Univ Med J 2018; 16(62):151-5.

34. Chander A, and Shrestha CD. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes 2013;6:487.
35. Raut S, Gokhale S, and Adhikari B. Prevalence of extended spectrum beta-lactamases among *Escherichia coli* and *Klebsiella* spp isolates in Manipal Teaching Hospital, Pokhara, Nepal. J Microbiol Infect Dis. 2015;5 Suppl 2:69-75.

36. Biswas SM, Ara N, Huda N, Andalib S, Rahman MH, and Mia MRA. Detection and antimicrobial susceptibility pattern of extended spectrum beta-lactamases (ESBLs) producing Gram-negative bacteria from different clinical samples. Puls. 2015;8:15-20.

37. Afridi FI, Farooqi BJ, and Hussain A. Frequency of extended-spectrum beta-lactamase producing Enterobacteriaceae among urinary pathogen isolates. J Coll Physicians Surgs Pak 2011;21 Suppl 12:741-4.

38. Khanfar HS, Bindayna KM, Senok AC, and Botta GA. ESBL-producers in the hospital and community settings J Infect Dev Ctries. 2009;3(4):295-9.

39. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, and Bush K. Multiply resistant *K. pneumoniae* strains from two Chicago Hospitals: identification of the extended-spectrum TEM-12 and TEM-10 Ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrob Agents Chemother. 1994;38:761–6.

40. Kazemian H, Heidari H, Ghanavati R, Ghafourian S, Yazdani F, Sadeghifard N, et al. Phenotypic and genotypic characterization of ESBL-, AmpC-, and carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates. Med Princ Pract. 2019;28:547-51.

41. Ny S, Kozlov R, Dumpis U, Edquist P, Hannuksela KGY, Kling AM, et al. Large variation in ESBL-producing *Escherichia coli* carries in six European countries including Russia. Eur J Clin Microbiol Infect Dis. 2018;37:2347-54.

42. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, and Weinstein RA. Multiple antibiotic-resistant *K. and E. coli* in nursing homes. JAMA. 1999;281:517–23.

43. Ogefere HO, Aigbiremwen PA, and Omorogie R (2015). Extended-Spectrum Beta-Lactamase (ESBL)–Producing Gram-negative Isolates from Urine and Wound Specimens in a Tertiary Health Facility in Southern Nigeria. Trop J Pharm Res. 2015;14(6):1089-94.

44. Moehring RW, Hazen KC, Hawkins MR, Drew RH, Sexton DJ, and Anderson DJ (2015). Challenges in Preparation of Cumulative Antibiogram Reports for Community Hospitals. J Clin Microbiol. 2015;53(9):2977–82.